Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has just reported fourth quarter of fiscal 2015 (4QFY15) earnings results, wherein earnings per share (EPS) surpassed the analysts’ estimates. However, revenue for the reported quarter was below expectations.
The pharmaceutical company posted EPS of $1.13, compared to the $1.10 expectation, but was lower than $1.30 in last year’s comparable quarter. Revenue was $700.87 million in the period, against the consensus forecast of $702.36 million, but higher than last year’s $599.48 million. Quarterly net product sales were reported to be $700.43 million, higher year-over-year (YoY) than $599.48 million.
Soliris’ sales increased by $89 million to $689 million, as opposed to the figure from last year’s same quarter. Strensiq net sales came in at $11.6 million. CEO David Hallal said: “2015 was a transformative year for Alexion, as we grew our complement franchise, commenced building a premier metabolic franchise with the global approvals of two new therapies, and simultaneously advanced the most robust rare disease pipeline in biotech.”
With regard to fiscal year 2016 (FY16), the company foresees EPS to be in the $5.31-5.51 range on a constant currency basis, against the $5.53 forecast. It expects the yearly revenue to be $3.17-3.22 billion, compared to the $3.19-billion estimate. On the other hand, Soliris’ revenue is expected to be in the $2.9-2.93 billion range.